Latest Search
Quote
| Back Zoom + Zoom - | ||||
|
<Research>Citi Raises FOSUN PHARMA's TP to HKD35.3, Re-focuses on R&D Monetization Potential
Recommend 6 Positive 6 Negative 4 |
||||
|
||||
|
Citi wrote in its research report that it had had a meeting with Guan Xiaohui, Co-Chairman of FOSUN PHARMA (02196.HK). Considering the company's attractive employee stock ownership plan targets, innovative pipeline valuation, and potential operational leverage effects, the broker raised its target price from HKD25 to HKD35.3, with a Buy rating. Citi also lifted its 2025-27 revenue/EPS forecasts for FOSUN PHARMA by 0.5%/ 2%/ 3% and by 3%/ 8%/ 6% to reflect its aggressive employee stock ownership targets, the ongoing monetization potential from out-licensing deals, and improved operational efficiency from R&D restructuring. AAStocks Financial News |
||||
Copied to Clipboard
 |
||||
